CommentaryAmifostine: a tonic or toxin to myeloid progenitors
References (37)
- et al.
Human pharmacokinetics of WR-2721
Int. J. Rad. Oncol. Biol. Phys.
(1986) - et al.
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
Blood
(1994) Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
Leuk. Res.
(1998)- et al.
Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence of glutathione status of Chinese hamster ovary cells
Biochem. Pharm.
(1995) - et al.
Structural specificity of polyamines and polyamine analogues in the protection of DNA from strand breaks induced by reactive oxygen species
Biochem. Biophys. Res. Commun.
(1998) - et al.
Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme
Cell
(1995) - et al.
Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells
J. Biol. Chem.
(1992) - et al.
Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors
Blood
(1999) - et al.
Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line
Leuk. Res.
(2000) - et al.
Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging
Blood
(1995)
Amifostine stimulates the formation of multipotent and erythroid hematopoietic progenitors
Leukemia
(1998)
Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection
Cancer Res.
(1988)
Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug
Cancer Res.
(1988)
Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721
Cancer Clin. Trials
(1981)
Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721
Cancer Res.
(1982)
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity
Semin. Oncol.
(1996)
Use of amifostine in hematologic malignancies in hematologic malignancies, myelodysplastic syndromes and acute leukemia
Semin. Oncol.
(1999)
Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278
Carcinogenesis
(1995)
Cited by (8)
Cytoprotective agents to avoid chemotherapy induced sideeffects on normal cells: A review
2019, Current Cancer Drug TargetsPotentiation of the antitumor effect of merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B
2006, Photochemistry and PhotobiologyAmifostine as differentiating agent in cord blood and bone marrow cultures from children with hematological disorders
2004, Pediatric Hematology and OncologyAmifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells
2003, Free Radical ResearchAmifostine inhibits angiogenesis in vivo
2003, Journal of Pharmacology and Experimental Therapeutics
Copyright © 2000 Elsevier Science Ltd. All rights reserved.